Development of an Orally Available and Central Nervous System (CNS)-Penetrant Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-à-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis

New therapies are needed for the treatment of toxoplasmosis, which is a disease caused by the protozoan parasite Toxoplasma gondii. To this end, we previously developed a potent and selective inhibitor (compound 1) of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) that possesses anti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Med Chem
Autors principals: Vidadala, Rama Subba Rao, Rivas, Kasey L., Ojo, Kayode K., Hulverson, Matthew A., Zambriski, Jennifer A., Bruzual, Igor, Schultz, Tracey L., Huang, Wenlin, Zhang, Zhongsheng, Scheele, Suzanne, DeRocher, Amy E., Choi, Ryan, Barrett, Lynn K., Siddaramaiah, Latha Kallur, Hol, Wim G. J., Fan, Erkang, Merritt, Ethan A., Parsons, Marilyn, Freiberg, Gail, Marsh, Kennan, Kempf, Dale, Carruthers, Vern B., Isoherranen, Nina, Doggett, J. Stone, Van Voorhis, Wesley C., Maly, Dustin J.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5100899/
https://ncbi.nlm.nih.gov/pubmed/27309760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.6b00760
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars